Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

20071,031 citationsJournal Articlebronze Open Access

Authors

William J. Sandborn · Mayo Clinic

S. B. Hanauer · University of Illinois Chicago

P. Rutgeerts · Universitair Ziekenhuis Leuven

Richard N. Fedorak · University of Alberta

M Lukas · Charles University

Donald MacIntosh · Dalhousie University

Remo Panaccione · University of Calgary

Abstract

Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn's disease naive to anti-TNF treatment.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Eosinophilic Esophagitis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gut

Volume 56, Issue 9, pp. 1232-1239

DOI: 10.1136/gut.2006.106781

Field-Weighted Citation Impact: 41.58